RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Lowers Price Target to $36

Benzinga · 1d ago
RBC Capital analyst Brian Abrahams maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from $37 to $36.